BMO Capital Maintains a Buy on BioNTech SE (BNTX)

BioNTech SE (NASDAQ:BNTX) is one of the top high growth international stocks to buy right now. On September 10, BMO Capital analyst Evan Seigerman maintained a Buy rating on BioNTech SE (NASDAQ:BNTX), keeping the price target at $143.00.

Why BioNTech SE (BNTX) Skyrocketed On Monday

The analyst stated that one of the primary reasons behind the optimistic rating is the anticipation of a stable COVID-19 vaccine business for BioNTech SE (NASDAQ:BNTX) in the near and medium term, potentially providing a strong revenue base.

Seigerman added that BioNTech SE (NASDAQ:BNTX) has an emerging pipeline with a number of catalysts that have the potential to drive share price appreciation, suggesting future growth.

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that creates messenger RNA (mRNA) therapeutics and vaccines to address serious diseases such as cancer and infectious diseases. It specializes in developing and manufacturing immunotherapies for patient-specific approaches.

While we acknowledge the potential of BNTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BNTX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.